Physician profile
Brian R Keegan
NPI 1053516351
$1,712,453.09
in general payments reported to CMS, 2019-2025
35 companies · $325K in 2025
The $325K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209K · 2020: $220K · 2021: $120K · 2022: $257K · 2023: $263K · 2024: $319K · 2025: $325K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $810K · Travel and Lodging: $74K · Food and Beverage: $16K · Consulting Fee: $5,288 · Education: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $810,060.00 |
| Travel and Lodging | $74,381.83 |
| Food and Beverage | $16,113.84 |
| Consulting Fee | $5,288.00 |
| Education | $326.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $407,038.91 | 2019-2025 | |
| Lilly USA, LLC | $351,407.63 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Amgen INC. | $298,582.17 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $230,403.43 | 2019-2025 | Tremfya, Simponi Aria |
| Incyte Corporation | $113,157.18 | 2021-2025 | Opzelura, Opzelura |
| Janssen Scientific Affairs, LLC | $110,779.94 | 2019-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $59,489.48 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $43,690.24 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $22,817.87 | 2019-2024 | Dupixent |
| Pfizer INC. | $21,450.46 | 2019-2025 | |
| Genzyme Corporation | $18,407.29 | 2021-2024 | |
| Leo Pharma INC. | $13,106.01 | 2019-2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $10,167.00 | 2019-2025 | Cabtreo, Siliq |
| Galderma Laboratories, L.P. | $7,044.05 | 2024-2025 | Nemluvio |
| Celgene Corporation | $4,152.32 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $231.80 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $99.08 | 2019-2023 | Ilumya |
| Mayne Pharma Commercial LLC | $91.47 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $62.56 | 2023-2025 | Zoryve |
| Dusa Pharmaceuticals, INC. | $37.17 | 2019 | |
| Merck Sharp & Dohme LLC | $26.47 | 2019 | |
| Genentech USA, INC. | $25.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.88 | 2025 | Spevigo |
| Journey Medical Corporation | $19.70 | 2025 | |
| Promius Pharma LLC | $14.69 | 2019 | |
| Aclaris Therapeutics, INC. | $14.56 | 2019 | |
| Epi Health, LLC | $14.54 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $14.36 | 2019 | |
| Almirall LLC | $13.95 | 2019 | |
| Dermavant Sciences, INC. | $13.86 | 2023 | Vtama |
| Dermira, INC. | $13.61 | 2019 | |
| Biofrontera INC. | $13.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Prugen, INC. Pharmaceuticals | $11.50 | 2019 | |
| Organon LLC | $7.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Keegan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.